

Message

From: Daniel Edlin [/O=THERANOS ORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DANIEL EDLIN]
Sent: 1/11/2014 12:48:34 AM
To: Daniel Young [/o=theranos organization/ou=first administrative group/cn=recipients/cn=dyoung]; Max Fosque [/o=theranos organization/ou=exchange administrative group (fydibohf23spdlt)/cn=recipients/cn=max fosque394]
Subject: RE: Demo Report for Review

Final report is attached...will send this one out

From: Max Fosque
Sent: Friday, January 10, 2014 3:57 PM
To: Daniel Young; Daniel Edlin
Subject: RE: Demo Report for Review

#1 I can do on both reports.

#2 I cannot do on v1 (because it is PDF editor)

From: Daniel Young
Sent: Friday, January 10, 2014 3:51 PM
To: Max Fosque; Daniel Edlin
Subject: RE: Demo Report for Review

The results looks fine.

For the reference ranges, can we remove all those extra "0"'s?

In the first report, can you make the HDL result go on the second page?

-Daniel

From: Max Fosque
Sent: Friday, January 10, 2014 3:21 PM
To: Daniel Young; Daniel Edlin
Subject: Demo Report for Review

Daniel Y, if you wouldn't mind quickly reviewing this report before its sent that would be great.

Dan Edlin, please decide which report would be preferable to send. If neither we can do a manual report from scratch.

Thanks,

Max

Max Fosque

Product Manager

Theranos, Inc.

Office: 650.470.6212 | Mobile: 650.704.2834

mfosque@theranos.com

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com



Theranos Lab Report Technology Demonstration

Theranos, Inc.
1601 S. California Ave, Palo Alto CA 94304

Khanna, Vivek

PATIENT INFORMATION

PATIENT NO.	987123671
D.O.B.	
AGE / GENDER	50 / M
PT MEDICATIONS	Unknown
ORDERING MD	N/A *Technology Demonstration*

TEST DETAIL

DATE COLLECTED	1/10/2014
SPECIMEN (S) COLLECTED	Blood
DATE REPORTED	1/10/2014
COMMENTS	Non-fasting *Technology Demonstration*

COMPREHENSIVE METABOLIC PANEL

TEST NAME	PATIENT'S RESULTS	REF. RANGE	UNITS
eGFR, non-African American			
eGFR, African-American			
Alkaline phosphatase			
Sodium			
Potassium			
Chloride			
Carbon Dioxide			
Glucose			
Urea Nitrogen			
Creatinine			
Calcium			
Protein, Total			
Albumin			
Bilirubin, Total			
Alanine Aminotransferase			
Aspartate Aminotransferase			

Key: L = Below Reference Range, H = Above Reference Range, WNL = Within Normal Limits, * = Critical Value

LIPID PANEL

TEST NAME	PATIENT'S RESULTS	REF. RANGE	UNITS
Cholesterol, Total			
Triglycerides			
HDL Cholesterol			
LDL Cholesterol			

Key: L = Below Reference Range, H = Above Reference Range, WNL = Within Normal Limits, * = Critical Value

End Of Report

Patient: Khanna, Vivek

Patient No: 987123671

Report date: 1/10/2014